Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma

被引:0
|
作者
Thomas E. Hutson
Ram Ganapathi
Paul Elson
Tarek Mekhail
Thomas Olencki
G. Thomas Budd
Ronald M. Bukowski
机构
[1] Cleveland Clinic Foundation;,Experimental Therapeutics Program, Taussig Cancer Center
[2] Cleveland Clinic Foundation;,Clinical Pharmacology Laboratory, Taussig Cancer Center
[3] Cleveland Clinic Foundation,Department of Hematology and Medical Oncology, Taussig Cancer Center
来源
Investigational New Drugs | 2004年 / 22卷
关键词
vinorelbine; phase I clinical trial; microtubule poisons; multi-drug resistance (MDR);
D O I
暂无
中图分类号
学科分类号
摘要
The anti-epileptic diphenylhydantoin (DPH; Dilantin®) selectively enhances the in vitro cytotoxicity of vinca microtubule poisons in both parent sensitive and multi-drug resistant (MDR) human tumor cells. The in vivo clinical activity of this combination has not been fully evaluated. Purpose: To determine the maximum tolerated dose (MTD), dose-limiting toxicities, and preliminary antitumor activity of the combination of intravenous (IV) bolus vinorelbine (VRL) and oral diphenylhydantoin (DPH) in patients (pts) with refractory solid tumors. Methods: Cohorts of 3–6 pts with refractory cancer were treated with escalating doses of weekly IV bolus VRL (I –20.0 mg/m2; II –22.5 mg/m2; III –25.0 mg/m2; IV –27.5 mg/m2; V –30.0 mg/m2; VI –32.5 mg/m2) combined with a fixed oral dose of DPH (400 mg/day) until MTD or progression. During each 35 day cycle, pts received DPH 400 mg/day administered orally on Days −6 to Day +22 and weekly IV bolus infusion of VRL on Days +1, +8, +15, and +22. The cohort treated at the MTD was expanded to further define toxicity. Results: A total of 25 evaluable pts. (9 men; 16 women) were treated with VRL and DPH at dose levels I (n = 5), II (n = 3), III (n = 2), IV (n = 3), V (n = 7) and VI (n = 5) in 5 week cycles over a 16 month period. Dose limiting toxicity occurred at dose level VI (VRL 32.5 mg/m2) and included grade 3 leukopenia (n = 2), grade 3 neutropenia (n = 1) and grade 4 neutropenia (n = 1) occurring within the first cycle of treatment. There were no responses, however 9 pts had stable disease of variable duration (8–56 weeks) and received a median of 2 cycles of treatment (range 2–14). Conclusion: Intravenous bolus administration of VRL and oral administration of a fixed dose of DPH was well tolerated according to the schedule reported here. Although there were no responses, several patients had prolonged disease stabilization. The recommended phase II dose of VRL when used in this combination is 30 mg/m2.
引用
收藏
页码:277 / 284
页数:7
相关论文
共 50 条
  • [1] Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma
    Hutson, TE
    Ganapathi, R
    Elson, P
    Mekhail, T
    Olencki, T
    Budd, GT
    Bukowski, RM
    INVESTIGATIONAL NEW DRUGS, 2004, 22 (03) : 277 - 284
  • [2] A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors
    Nancy W. Peacock
    Howard A. Burris
    Veronique Dieras
    Lon Smith
    Gladys I. Rodriguez
    John R. Eckardt
    Suzanne Fields Jones
    Joanne Hardy
    John Hohneker
    Joseph Bigley
    Daniel D. Von Hoff
    Investigational New Drugs, 1998, 16 : 37 - 43
  • [3] A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors
    Peacock, NW
    Burris, HA
    Dieras, V
    Smith, L
    Rodriguez, GI
    Eckardt, JR
    Jones, SF
    Hardy, J
    Hohneker, J
    Bigley, J
    Von Hoff, DD
    INVESTIGATIONAL NEW DRUGS, 1998, 16 (01) : 37 - 43
  • [4] Phase I/II trial of combination topotecan and vinorelbine in patients with refractory gynecologic cancer.
    Berchuck, A
    Secord, AA
    Havrilesky, LJ
    Wenham, R
    Soper, JT
    Clarke-Pearson, DL
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 487S - 487S
  • [5] Phase I trial of docetaxel and vinorelbine in patients with advanced nonsmall cell lung carcinoma
    Miller, VA
    Ng, KK
    Krug, LM
    Perez, W
    Pizzo, B
    Heelen, RT
    Kris, MG
    CANCER, 2000, 88 (05) : 1045 - 1050
  • [6] Phase I/II trial of infusional vinorelbine in relapsed or refractory lymphoma.
    Sarris, AH
    Psyrri, A
    Romaguera, J
    Hagemeister, F
    McLaughlin, P
    Bachier, C
    Mesina, O
    Adams, LM
    Cabanillas, F
    BLOOD, 1998, 92 (10) : 621A - 621A
  • [7] Phase I trial of topotecan plus vinorelbine with/without filgrastim (G-CSF) in patients with refractory malignancies
    Hanna, NH
    Gordon, MS
    Fife, K
    Sandler, AB
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (04): : 337 - 339
  • [8] Phase I trial of gemcitabine and vinorelbine in patients with refractory solid tumors: efficacy with minimal toxicity in a geriatric population
    Radice, P
    Koletsky, A
    Greenhawt, M
    Frankel, C
    Pearce, P
    Byrne, C
    Jahanzeb, M
    ANNALS OF ONCOLOGY, 1998, 9 : 79 - 79
  • [9] Phase I trial of metronomic oral vinorelbine in patients with advanced cancer
    Rajdev, Lakshmi
    Negassa, Abdissa
    Dai, Qun
    Goldberg, Gary
    Miller, Kathy
    Sparano, Joseph A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (05) : 1119 - 1124
  • [10] Phase I trial of metronomic oral vinorelbine in patients with advanced cancer
    Lakshmi Rajdev
    Abdissa Negassa
    Qun Dai
    Gary Goldberg
    Kathy Miller
    Joseph A. Sparano
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 1119 - 1124